Cardiac Imaging Techniques in Systemic Autoimmune Diseases

Handbook of Systemic Autoimmune Diseases

Volumn 1, Issue , 2003, Pages 107-119

  Turiel, Maurizio ^a   Sarzi Puttini, Piercarlo ^b   Cervera, Ricard ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649653636     PISSN: 15715078     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1571-5078(03)01008-0     Document Type: Review

References (39)

1. Asherson R.A., and Cervera R. Antiphospholipid antibodies and heart. Lessons and pitfalls for the cardiologist. Circulation 84 (1991) 920
2. Bijl M., Brouwer J., and Kallemberg G.G.M. Grand rounds from international lupus centres. Cardiac abnormalities in SLE: pancarditis. Lupus 9 (2000) 236
3. Black I.W., Hopkins A.P., Lee L.C.L., et al. Left atrial spontaneous echo contrast: a clinical and echocardiographic analysis. J. Am. Coll. Cardiol. 18 (1991) 398
4. Braunwald E. Heart Disease: A Textbook of Cardiovascular Medicine. 5th ed. (1997), Saunders, London p. 1776
5. Brenner B., Blumenfeld Z., Markiewicz W., et al. Cardiac involvement in patients with primary antiphospholipid syndrome. J. Am. Coll. Cardiol. 18 (1991) 931
6. Candell-Riera J., Armadans-Gil L., Simeon C.P., et al. Comprehensive noninvasive assessment of cardiac involvement in limited systemic sclerosis. Arthritis Rheum. 39 (1996) 1138
7. Cervera R. Recent advances in antiphospholipid antibody-related valvulopathies. J. Autoimmun. 15 (2000) 123
8. Cervera R., Khamashta A., Font J., et al. High prevalence of significant heart valve lesion in patients with the primary antiphospholipid syndrome. Lupus 1 (1991) 43
9. Cervera R., Font J., Paré C., et al. Cardiac disease in systemic lupus erythematosus. Prospective study of 70 patients. Ann. Rheum. Dis. 51 (1992) 156
10. Cheitlin M.S., Alpert J.S., Armstrong W.F., et al. ACC/AHA guidelines for the clinical application of echocardiography: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). J. Am. Coll. Cardiol. 29 (1997) 862
11. Deswall A., and Follansbee W.P. Cardiac involvement in scleroderma. Rheum. Dis. Clin. North Am. 22 (1996) 841
12. Eichenberger A.C., Schuiki E., Kochli D.V., et al. Ischaemic heart disease: assessment with gadolinium-enhanced ultrafast MR imaging and dipyridamole stress. J. Magn. Reson. Imag. 4 (1994) 425
13. Espinola-Zavaleta N., Vargas-Barracòn J., Colmenares-Galvis T., et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am. Heart J. 137 (1999) 973
14. Ferri C., Bernini L., Bongiorni M.G., et al. Noninvasive evaluation of cardiac dysrhythmias, and their relationship with systemic symptoms, in progressive systemic sclerosis. Arthritis Rheum. 28 (1985) 1259
15. Ferri C., Di Bello V., Martini A., et al. Heart involvement in systemic sclerosis: an ultrasonic tissue characterisation study. Ann. Rheum. Dis. 57 (1998) 296 This study evaluates SSc patients by ultrasonic videodensitometric analysis, a non-invasive method that can detect early myocardial changes related to both fibrosis and microcirculatory abnormalities
16. Follansbee W.P., Curtiss E.I., Rahko P.S., et al. The electrocardiogram in systemic sclerosis (scleroderma). Study of 102 consecutive cases with functional correlations and review of the literature. Am. J. Med. 79 (1985) 183
17. Galve E., Ordi J., Barquinero J., et al. Valvular heart disease in the primary antiphospholipid syndrome. Ann. Intern. Med. 116 (1992) 293
18. Ghaffary S. Detection and management of coronary artery disease in patients with rheumatological disorders. Rheum. Dis. Clin. North Am. 25 (1999) 657
19. Giunta A., Picillo U., Maione S., et al. Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. Acta Cardiol. 2 (1993) 183
20. Goodson N. Coronary artery disease and rheumatoid arthritis. Curr. Opin. Rheumatol. 14 (2002) 115
21. Guedes C., Bianchi-Fior P., Cormier B., et al. Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients. Arthritis Rheum. 45 (2001) 129 This study analyzed 30 unselected rheumatoid arthritis patients by means of transesophageal echocardiography to evaluate the incidence and type of heart lesions. Cardiac involvement, particularly of the mitral valve, is extremely common in these patients
22. Hasnie A.M., Stoddard M.F., Gleason C.B., et al. Diastolic dysfunction is a feature of the antiphospholipid syndrome. Am. Heart J. 129 (1995) 1009
23. Hojnik M., George J., Ziporen L., et al. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93 (1996) 1579
24. Ishida R., Murata Y., Sawada Y., et al. Thallium-201 myocardial SPET in patients with collagen disease. Nucl. Med. Commun. 21 (2000) 729
25. Jafar M.Z., Morgan M.C., and Gorcsan III J. Transesophageal echocardiographic detection of multiple mitral valve masses in primary antiphospholipid syndrome with stroke. Am. Heart J. 127 (1994) 445
26. Jiménez S., Ramos-Casals M., Cervera R., et al. Atherosclerosis in systemic lupus erythematosus: clinical relevance. In: Shoenfeld Y., Harats D., and Wick G. (Eds). Atherosclerosis and Autoimmunity (2001), Elsevier, Amsterdam 255
27. Johns J.P., Abraham S.A., and Eagle K.A. Dipyridamol-thallium versus dobutamine echocardiographic stress testing: a clinician's view point. Am. Heart J. 130 (1995) 373
28. Kahan A., Devaux J., Amor B., et al. The effect of captopril on thallium 201 myocardial perfusion in systemic sclerosis. Clin. Pharmacol. Ter. 47 (1990) 483
29. Khamashta M.A., Cervera R., Asherson R.A., et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet 335 (1990) 1541
30. Lee T.H., and Boucher C.A. Noninvasive tests in patients with stable coronary artery disease. N. Engl. J. Med. 344 (2001) 1840 These authors review the indications of noninvasive tests in patients with known or suspected coronary heart disease. No single test or strategy has been proved to be superior to the others. The authors report their guidelines for these tests
31. Legrand V., Raskinet B., Laarman G., et al. Diagnostic value of exercise electrocardiography and angina after coronary artery stenting. Benestent Study Group. Am. Heart J. 133 (1997) 240
32. Manzi S., Kuller L.H., Edmundowicz D., et al. Vascular imaging: changing the face of cardiovascular research. Lupus 9 (2000) 176
33. Metz D., Jolly D., Graciet-Richard J., et al. Prevalence of valvular involvement in systemic lupus erythematosus and association with antiphospholipid syndrome: a matched echocardiographic study. Cardiology 85 (1994) 129
34. Moser D.K., Stevenson W.G., Woo M.A., et al. Frequency of late potentials in systemic sclerosis. Ann. Cardiol. 67 (1991) 541
35. Nihoyannopoulos P., Gomez P.M., Joshi J., et al. Cardiac abnormalities in systemic lupus erythematosus. Circulation 82 (1990) 369
36. Omdal R., Lunde P., Rasmussen K., et al. Transesophageal and transthoracic echocardiography and Doppler-examinations in systemic lupus erythematosus. Scand. J. Rheumatol. 30 (2001) 275 This study examined 35 patients with SLE by 2D transthoracic and transesophageal echocardiography. Valve thickening and valve masses, often in combination, are the most frequent lesions in SLE patients (46%) and occur more often on the aortic than on the mitral valves
37. Plazak W., Zabinska-Plazak E., Wojas-Pelc A., et al. Heart structure and function in systemic sclerosis. Eur. J. Dermatol. 12 (2002) 257
38. Roldan C.A., Shively B.K., and Crawford M.H. An echocardiographic study of valvular heart disease associated with systemic lupus erythematosus. N. Engl. J. Med. 335 (1996) 1424 The authors studied 69 SLE patients by transesophageal echocardiography with a long-term follow-up of 57 months. Valvular heart diseases were common on the initial and the follow-up echocardiograms (61 and 53%, respectively). An important finding in this study is that over time valvular abnormalities frequently resolve or change and new ones often develop. The authors also demonstrated that most of the complications were related to valvular disease
39. Turiel M., Muzzupappa S., Gottardi B., et al. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 9 (2000) 406 The authors performed a transesophageal echocardiographic study in a group of 40 patients with primary antiphospholipid syndrome (PAPS) to describe the prevalence of cardiac abnormalities or potential embolic sources. Cardiac involvement was present in 82% of these patients. PAPS patients with aCL titer >40 GPL-U represent a higher risk group for thromboembolic events